Lung Cancer remains one of the most widely studied malignancies due to its global impact on cancer incidence and mortality. It develops when abnormal cells in lung tissue grow uncontrollably and form tumors that can interfere with normal respiratory function. Research on prevention, screening, and therapeutic innovation is frequently highlighted at international scientific forums such as a Cancer Conference, where clinicians and researchers discuss emerging strategies for diagnosis and management of pulmonary malignancy across diverse patient populations.

The development of lung cancer is strongly associated with environmental and lifestyle factors that cause genetic mutations in lung epithelial cells. Tobacco smoke exposure remains the most significant risk factor, although other contributors such as air pollution, occupational carcinogens, and inherited susceptibility can also influence disease risk. Over time, repeated cellular damage may lead to the accumulation of genetic alterations affecting pathways responsible for cell division, DNA repair, and apoptosis. These changes can initiate malignant transformation and allow tumor cells to proliferate and invade surrounding tissues.

Lung cancer is broadly categorized into two main clinical groups based on histological and biological features. Non-small cell lung cancer represents the majority of cases and includes subtypes such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Small cell lung cancer, while less common, is typically more aggressive and characterized by rapid growth and early metastasis. Accurate classification is essential because treatment decisions depend heavily on tumor subtype, stage, and molecular characteristics identified through diagnostic testing.

Early detection of lung cancer significantly improves the chances of successful treatment. Low-dose computed tomography screening has become an important strategy for identifying tumors in high-risk individuals before symptoms appear. When lung cancer is diagnosed, staging evaluations determine whether the disease is localized, regionally advanced, or metastatic. This staging information guides treatment planning and helps predict patient outcomes.

Treatment approaches for lung cancer often involve a combination of surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy depending on disease stage and tumor biology. Advances in molecular diagnostics have enabled physicians to identify genetic mutations that can be targeted with specific drugs, improving treatment effectiveness and reducing unnecessary toxicity. Immunotherapy has also emerged as an important therapeutic option by enhancing the immune system’s ability to recognize and destroy cancer cells. Ongoing research continues to investigate new treatment combinations, biomarkers for therapy response, and innovative diagnostic technologies aimed at improving survival and quality of life for individuals diagnosed with lung cancer.